Clinical Trial Update: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study of IO-108 as a single agent and in combination with a PD-1 inhibitor in adults with advanced solid tumors has completed, assessing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• IO-108 (IO-108)
• PD-1 immune checkpoint inhibitor (PD-1 inhibitor)

Snippet

Sponsor: Immune-Onc Therapeutics | Conditions: Solid Tumor, Adult | Phase 1 | Status: COMPLETED